Cerebellar Superficial Siderosis in Cerebral Amyloid Angiopathy

NCT05394636 | Completed

• 1 other identifier: Local/2022/Dr-02
• Study Type: observational
• Target: 111
• Locations: 1 country
• Sites: 1

Brief Summary

Cerebellar superficial siderosis (SS) has been recently reported to be present in about 10% of both hereditary (n=50) and sporadic (n=46) cerebral amyloid angiopathy (CAA) patients on 3T MRI using susceptibility-weighted imaging (SWI) in the majority of patients. In that study, cerebellar SS was associated with a higher number of supratentorial lobar and superficial cerebellar macrobleeds (although cerebellar SS was not directly located adjacent to these cerebellar macrobleeds). It is unclear if cerebellar SS is caused by in situ leakage of cerebellar leptomeningeal vessels or rather represents hemorrhagic diffusion from cerebellar parenchymal micro/macrobleeds or from supratentorial bleeding sources via the tentorium cerebelli (TC).

Conditions

Cerebral Amyloid Angiopathy; Siderosis

Outcome Measures

Primary Outcomes (9)

• MRI analyse : presence of cerebellar SS

  presence of cerebellar SS (Yes/No)

  baseline

• MRI analyse : Location of cerebellar SS

  Location of cerebellar SS (vermis, anterior lobe, posterior lobe)

  baseline

• MRI analyse : characteristics of cerebellar SS

  number of cerebellar sulci involved

  baseline

• MRI analyse : characteristics of cerebellar SS

  spatial relationship with cerebellar micro- and macrobleeds

  baseline

• MRI analyse : Presence of cerebellar macrobleeds

  Presence of cerebellar macrobleeds (Yes/No)

  baseline

• MRI analyse : Presence of cerebral macrobleeds

  Presence of cerebral macrobleeds (Yes/No)

  baseline

• MRI analyse : Characteristics of cerebral macrobleeds

  spatial relationship of cerebral macrobleeds with the TC \[adjacent vs. non-adjacent to TC\]

  baseline

• MRI analyse : Characteristics of cortical SS

  spatial relationship with TC (adjacent vs. non-adjacent to TC)

  baseline

• MRI analyse : hemosiderin

  presence of hemosiderin deposition along the TC.

  baseline

Study Arms (1)

cerebral amyloid angiopathy (CAA)

Clinical and 1.5T MRI T2\*-weighted imaging characteristics analyses from sporadic probable CAA patients (according to the modified Boston criteria) presenting with acute symptoms related to acute ICH, acute subarachnoid haemorrhage, or cortical SS,

Other: None, pure observational study

Interventions

None, pure observational study OTHER

None, pure observational study

cerebral amyloid angiopathy (CAA)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Sporadic probable CAA patients (according to the modified Boston criteria) presenting with acute symptoms related to acute ICH, acute subarachnoid haemorrhage, or cortical SS, between September 2009 and January 2022 in Nîmes University Hospital, France

You may qualify if:

• CAA patients (according to the modified Boston criteria)
• with acute symptoms related to acute ICH, acute subarachnoid haemorrhage, or cortical SS

You may not qualify if:

• Patients with recent trauma,
• Patients with anticoagulation treatment,
• Patients with pathological blood coagulation tests (activated partial thromboplastin time \[aPTT\] ratio=patient's aPTT/normal control aPTT\] \>1.2; or partial thromboplastin time \[PTT\] \<75%) or platelet count (\<100 x 109/L)
• Patients with inflammatory CAA

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Nīmes: lead

Study Sites (1)

CHU de Nîmes

Nîmes, 30029, France

Location

Related Publications (1)

• Renard D, Laurent-Chabalier S, Leonte A, Hackius M, Parvu T, Wacongne A, Thouvenot E. Cerebellar Superficial Siderosis in Cerebral Amyloid Angiopathy on 1.5T T2*-Weighted Imaging. Cerebrovasc Dis. 2023;52(6):706-710. doi: 10.1159/000528384. Epub 2023 Mar 6.

  PMID: 36878206 RESULT

MeSH Terms

Conditions

Cerebral Amyloid Angiopathy; Siderosis

Condition Hierarchy (Ancestors)

Cerebral Arterial Diseases; Intracranial Arterial Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Amyloidosis; Proteostasis Deficiencies; Metabolic Diseases; Nutritional and Metabolic Diseases; Pneumoconiosis; Lung Diseases, Interstitial; Lung Diseases; Respiratory Tract Diseases; Lung Injury; Occupational Diseases

Study Officials

• Anissa MEGZARI

  Centre Hospitalier Universitaire de Nīmes

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 24, 2022
• First Posted: May 27, 2022
• Study Start: June 1, 2022
• Primary Completion: December 31, 2022
• Study Completion: December 31, 2022
• Last Updated: December 4, 2025

Record last verified: 2022-12

Locations

FR (1)